INSM Earnings Date: Feb 18, 2027 (Estimated) — Insmed Incorporated
NASDAQ · Healthcare · Medical - Pharmaceuticals
Updated
When is INSM's next earnings date?
Insmed Incorporated (INSM) is expected to report Q4 2026 earnings on Thursday, February 18, 2027 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.31 on revenue of $566.4M.
How did INSM do in its last earnings report?
In its most recent report on Oct 29, 2026 (Q3 2026), Insmed Incorporated posted EPS of -$0.46 versus the -$0.38 estimate, a miss of 20.2%. Revenue was $524.4M against a $500.4M estimate. The stock's 1-day post-earnings move was +15.1%.
How much does INSM stock move after earnings?
INSM beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 12.7% (up or down) in the day after earnings.
About Insmed Incorporated
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
🤖 AI Earnings Analysis
Insmed’s launch momentum is compelling: BRINSUPRI generated $400.1 million, driving total revenue to $524.4 million, 6673% higher year over year and above consensus. The $0.46 loss missed estimates, but revenue guidance of $1.7–$1.9 billion supports a strong growth outlook.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | Q3 2026 | -0.38 | -0.46 | -20.19% | $524.4M | ❌ Miss | +15.06% | — | — |
| 2026-08-06 | Q2 2026 | -0.67 | -0.06 | +91.89% | $425.5M | ✅ Beat | +33.86% | +33.59% | +27.93% |
| 2026-05-07 | Q1 2026 | -0.98 | -0.76 | +22.45% | $306.0M | ✅ Beat | -23.41% | -13.93% | -31.27% |
| 2026-02-19 | Q4 2025 | -1.13 | -1.54 | -36.28% | $263.8M | ❌ Miss | +6.54% | -1.65% | -4.71% |
| 2025-10-30 | Q3 2025 | -1.35 | -1.75 | -29.63% | $142.3M | ❌ Miss | +16.33% | +11.94% | +24.45% |
| 2025-08-07 | Q2 2025 | -1.31 | -1.70 | -29.77% | $107.4M | ❌ Miss | -1.76% | +10.44% | +30.42% |
| 2025-02-20 | Q4 2024 | -1.16 | -1.32 | -13.79% | $104.4M | ❌ Miss | -0.26% | -6.84% | -6.04% |
| 2024-10-31 | Q3 2024 | -1.22 | -1.27 | -4.10% | $93.4M | ❌ Miss | -4.29% | +3.65% | +6.92% |
Showing last 8 quarters.